Lataa...
Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM
BACKGROUND: Mechanisms of inflammation and protein accumulation are crucial in inclusion body myositis (IBM). Recent evidence demonstrated that intravenous immunoglobulin failed to suppress cell-stress mediators in IBM. Here we studied the molecular changes in skeletal muscle biopsies from patients...
Tallennettuna:
| Julkaisussa: | BMC Neurol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4833914/ https://ncbi.nlm.nih.gov/pubmed/27083892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-016-0568-5 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|